Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system
Background Abemaciclib, an oral kinase inhibitor, is used to treat hormone receptor–positive and HER2-negative breast cancer patients. However, there has been a decrease in studies reporting adverse reactions to abemaciclib-related kidney injuries. Thus, this study was aimed at assessing its safety...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605251325961 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|